Correct Answer: C. Edrophonium
Edrophonium is a short-acting anticholinesterase used specifically for the Tensilon test (edrophonium challenge test) to differentiate myasthenia gravis (MG) from cholinergic crisis. The discriminating principle: in MG, anticholinesterase drugs improve muscle weakness by increasing acetylcholine at the neuromuscular junction; in cholinergic crisis, anticholinesterase worsens symptoms by further increasing acetylcholine, causing a depolarizing block. Edrophonium's rapid onset (30–60 seconds IV) and short duration (5–10 minutes) make it ideal for diagnostic testing. When edrophonium is given IV to an MG patient, there is prompt improvement in muscle strength (positive test). In cholinergic crisis, symptoms worsen (negative test). This differential response is the gold standard for distinguishing the two conditions in acute settings. Edrophonium is preferred over longer-acting agents like neostigmine because its brief action allows safe reversal if cholinergic crisis is inadvertently triggered. In Indian clinical practice, the Tensilon test remains a key bedside diagnostic tool in neurology units when serology (anti-acetylcholine receptor antibodies) is unavailable or results are pending.
Why the other options are wrong
A. Donepezil — Donepezil is a long-acting, selective acetylcholinesterase inhibitor used for Alzheimer's disease. Its prolonged duration (>24 hours) makes it unsuitable for acute diagnostic testing. It cannot be rapidly reversed if cholinergic toxicity occurs, and it does not provide the immediate clinical response needed to differentiate MG from cholinergic crisis in real-time. B. Obidoxime — Obidoxime is an oxime used to reactivate acetylcholinesterase in organophosphate poisoning by removing the phosphoryl group. It does not differentiate MG from cholinergic crisis; it is a treatment for poisoning, not a diagnostic agent. It has no role in the Tensilon test or MG diagnosis. D. Atropine — Atropine is a muscarinic antagonist used to treat cholinergic toxicity (e.g., in organophosphate poisoning). It blocks acetylcholine effects but does not improve MG symptoms and cannot differentiate MG from cholinergic crisis. Atropine is a treatment for cholinergic excess, not a diagnostic tool.
High-Yield Facts
- Edrophonium (Tensilon test): IV anticholinesterase with onset 30–60 seconds and duration 5–10 minutes; gold standard for acute MG diagnosis.
- MG response to edrophonium: Muscle strength improves within seconds (positive test); confirms neuromuscular transmission defect.
- Cholinergic crisis response to edrophonium: Symptoms worsen (negative test); indicates acetylcholine excess, not deficiency.
- Anticholinesterases in MG: Neostigmine (oral, 15–30 mg) is used for long-term management; edrophonium is reserved for acute diagnosis only.
- Serology alternatives: Anti-AChR antibodies (80% MG-seropositive) and anti-MuSK antibodies (40% seronegative MG) are now preferred diagnostic methods in Indian tertiary centers.
Mnemonics
TENSILON = Transient, Excellent, Neuro, Short-acting, Immediate, Lasts Only Ninety seconds Edrophonium's key properties: transient effect, excellent for diagnosis, short-acting (90 seconds), immediate onset. Use when you need rapid MG confirmation at the bedside. MG + Edrophonium = BETTER; Cholinergic + Edrophonium = WORSE In MG, anticholinesterase improves weakness (more ACh helps). In cholinergic crisis, it worsens (too much ACh already). This opposite response is the diagnostic key.
NBE Trap
NBE may pair edrophonium with neostigmine to confuse students about which anticholinesterase is used for acute diagnosis vs. chronic management. Edrophonium is diagnostic (Tensilon test); neostigmine is therapeutic (long-term MG treatment).
Clinical Pearl
In Indian neurology practice, when a patient presents with acute weakness and respiratory compromise, the Tensilon test can be life-saving: a positive response confirms MG and guides immediate anticholinesterase therapy, while a negative response raises suspicion for cholinergic crisis, prompting atropine and supportive care instead.
_Reference: KD Tripathi Pharmacology Ch. 7 (Cholinergic Drugs); Harrison Ch. 382 (Myasthenia Gravis)_